Pitavastatin as the preferred statin for control of dyslipidemia in patients with HIV infection using antiretrovirals

Detalhes bibliográficos
Autor(a) principal: Monteiro Borges da Silva Valente, Thiago José
Data de Publicação: 2023
Outros Autores: Pacífico, Fernando Augusto, Campos Falcão, Antônio Diego
Tipo de documento: Artigo
Idioma: por
eng
Título da fonte: Anais da Faculdade de Medicina de Olinda (Online)
Texto Completo: https://afmo.emnuvens.com.br/afmo/article/view/279
Resumo: Objective: explain why pitavastatin is the lipid-lowering agent of choice for lipid control and cardiovascular risk reduction in people infected with HIV. Methods: Searches were carried out inPubMed and the Virtual Health Library (VHL), using these descriptors, in English and Portuguese: “Pitavastatin”, “HIV”, “Statins”, “Infected by HIV”, “Dyslipidemia” and “Antiretrovirals”. 46 articles were retrieved, reduced, after refinement, to 9, 6 from PubMed and 3 from VHL. Results: The use of antiretrovirals (ARVs) significantly increases lipid alterations in HIV-infected people and should be associated with lipid-lowering therapy with statins. However, as most of them are metabolized by the cytochrome P450 3A4 system, which is inhibited by some ARVs, pitavastatin stands out, since its metabolization process occurs primarily by glucuronidation. Furthermore, it was provedthat this statin showed more inflammatory markers and LDL-c levels than pravastatin, which is metabolized through the same mechanism. Conclusion: Therefore, pitavastatin is preferably the lipid-lowering agent to correct dyslipidemia in HIV-infected patients, due to its minimal drug reactions and greater reduction in lipids and inflammatory markers.
id FMO-1_d2c19ab9ac4120e6cdd0b54af9b6e41f
oai_identifier_str oai:ojs.afmo.emnuvens.com.br:article/279
network_acronym_str FMO-1
network_name_str Anais da Faculdade de Medicina de Olinda (Online)
repository_id_str
spelling Pitavastatin as the preferred statin for control of dyslipidemia in patients with HIV infection using antiretroviralsPitavastatina como estatina de escolha para o controle da dislipidemia em pacientes infectados pelo HIV em uso de antirretroviraisAntirretroviraisHIVHiperlipidemiaHipolipemiantesEstatinasAntiretroviralsHIVHyperlipidemiaHypolipidemicStatinsObjective: explain why pitavastatin is the lipid-lowering agent of choice for lipid control and cardiovascular risk reduction in people infected with HIV. Methods: Searches were carried out inPubMed and the Virtual Health Library (VHL), using these descriptors, in English and Portuguese: “Pitavastatin”, “HIV”, “Statins”, “Infected by HIV”, “Dyslipidemia” and “Antiretrovirals”. 46 articles were retrieved, reduced, after refinement, to 9, 6 from PubMed and 3 from VHL. Results: The use of antiretrovirals (ARVs) significantly increases lipid alterations in HIV-infected people and should be associated with lipid-lowering therapy with statins. However, as most of them are metabolized by the cytochrome P450 3A4 system, which is inhibited by some ARVs, pitavastatin stands out, since its metabolization process occurs primarily by glucuronidation. Furthermore, it was provedthat this statin showed more inflammatory markers and LDL-c levels than pravastatin, which is metabolized through the same mechanism. Conclusion: Therefore, pitavastatin is preferably the lipid-lowering agent to correct dyslipidemia in HIV-infected patients, due to its minimal drug reactions and greater reduction in lipids and inflammatory markers.Objetivo: explicar o porquê da pitavastatina ser o hipolipemiante de escolha para controle lipídico e redução do risco cardiovascular em pessoasinfectadas pelo HIV. Métodos: Realização de buscas na PubMed e na Biblioteca Virtual em Saúde (BVS), com uso destes descritores, em inglês e português: “Pitavastatina”, “HIV”, “Estatinas”, “Infectados pelo HIV”, “Dislipidemia” e “Antirretrovirais”. Foram recuperados 46 artigos, reduzidos, após o refinamento, a 9, sendo 6 da PubMed e 3 da BVS. Resultados: O uso de antirretrovirais (ARV) aumenta significativamente as alterações lipídicas em pessoas infectadas pelo HIV, devendo ser associado à terapia hipolipemiante com as estatinas. Mas, como a maioria é metabolizada pelo sistema do citocromo P450 3A4, inibido por alguns ARV, destaca-sea pitavastatina, visto que seu processo de metabolização ocorre, primariamente, por glucoronidação. Além disso, comprovou-se que esta estatina reduziu mais significativamente os marcadores inflamatórios e os níveis do LDL-c, do que a pravastatina, cuja metabolização é através do mesmo mecanismo. Conclusão: Portanto, a pitavastatina é, preferencialmente, o hipolipemiante para corrigir a dislipidemia em pacientes infectados pelo HIV, devido às suas mínimas interações medicamentosas e maior redução lipídica e dos marcadores inflamatórios. Conclusão: A pitavastatina é, preferencialmente, o hipolipemiante para corrigir a dislipidemia em pacientes infectados pelo HIV, devido às suas mínimas interações medicamentosas e maior redução lipídica e dos marcadores inflamatórios.Faculdade de Medicina de Olinda2023-12-22info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://afmo.emnuvens.com.br/afmo/article/view/27910.56102/afmo.2023.279Annals of Olinda Medical School; Vol. 1 No. 10 (2023); 83-95Anais da Faculdade de Medicina de Olinda; v. 1 n. 10 (2023); 83-952674-84872595-1734reponame:Anais da Faculdade de Medicina de Olinda (Online)instname:Faculdade de Medicina de Olinda (FMO)instacron:FMOporenghttps://afmo.emnuvens.com.br/afmo/article/view/279/164https://afmo.emnuvens.com.br/afmo/article/view/279/163Copyright (c) 2023 Thiago José Monteiro Borges da Silva Valentehttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessMonteiro Borges da Silva Valente, Thiago JoséPacífico, Fernando AugustoCampos Falcão, Antônio Diego2023-12-22T18:35:03Zoai:ojs.afmo.emnuvens.com.br:article/279Revistahttps://afmo.emnuvens.com.br/afmoPUBhttps://afmo.emnuvens.com.br/afmo/oaianaisfmo@fmo.edu.br2674-84872595-1734opendoar:2023-12-22T18:35:03Anais da Faculdade de Medicina de Olinda (Online) - Faculdade de Medicina de Olinda (FMO)false
dc.title.none.fl_str_mv Pitavastatin as the preferred statin for control of dyslipidemia in patients with HIV infection using antiretrovirals
Pitavastatina como estatina de escolha para o controle da dislipidemia em pacientes infectados pelo HIV em uso de antirretrovirais
title Pitavastatin as the preferred statin for control of dyslipidemia in patients with HIV infection using antiretrovirals
spellingShingle Pitavastatin as the preferred statin for control of dyslipidemia in patients with HIV infection using antiretrovirals
Monteiro Borges da Silva Valente, Thiago José
Antirretrovirais
HIV
Hiperlipidemia
Hipolipemiantes
Estatinas
Antiretrovirals
HIV
Hyperlipidemia
Hypolipidemic
Statins
title_short Pitavastatin as the preferred statin for control of dyslipidemia in patients with HIV infection using antiretrovirals
title_full Pitavastatin as the preferred statin for control of dyslipidemia in patients with HIV infection using antiretrovirals
title_fullStr Pitavastatin as the preferred statin for control of dyslipidemia in patients with HIV infection using antiretrovirals
title_full_unstemmed Pitavastatin as the preferred statin for control of dyslipidemia in patients with HIV infection using antiretrovirals
title_sort Pitavastatin as the preferred statin for control of dyslipidemia in patients with HIV infection using antiretrovirals
author Monteiro Borges da Silva Valente, Thiago José
author_facet Monteiro Borges da Silva Valente, Thiago José
Pacífico, Fernando Augusto
Campos Falcão, Antônio Diego
author_role author
author2 Pacífico, Fernando Augusto
Campos Falcão, Antônio Diego
author2_role author
author
dc.contributor.author.fl_str_mv Monteiro Borges da Silva Valente, Thiago José
Pacífico, Fernando Augusto
Campos Falcão, Antônio Diego
dc.subject.por.fl_str_mv Antirretrovirais
HIV
Hiperlipidemia
Hipolipemiantes
Estatinas
Antiretrovirals
HIV
Hyperlipidemia
Hypolipidemic
Statins
topic Antirretrovirais
HIV
Hiperlipidemia
Hipolipemiantes
Estatinas
Antiretrovirals
HIV
Hyperlipidemia
Hypolipidemic
Statins
description Objective: explain why pitavastatin is the lipid-lowering agent of choice for lipid control and cardiovascular risk reduction in people infected with HIV. Methods: Searches were carried out inPubMed and the Virtual Health Library (VHL), using these descriptors, in English and Portuguese: “Pitavastatin”, “HIV”, “Statins”, “Infected by HIV”, “Dyslipidemia” and “Antiretrovirals”. 46 articles were retrieved, reduced, after refinement, to 9, 6 from PubMed and 3 from VHL. Results: The use of antiretrovirals (ARVs) significantly increases lipid alterations in HIV-infected people and should be associated with lipid-lowering therapy with statins. However, as most of them are metabolized by the cytochrome P450 3A4 system, which is inhibited by some ARVs, pitavastatin stands out, since its metabolization process occurs primarily by glucuronidation. Furthermore, it was provedthat this statin showed more inflammatory markers and LDL-c levels than pravastatin, which is metabolized through the same mechanism. Conclusion: Therefore, pitavastatin is preferably the lipid-lowering agent to correct dyslipidemia in HIV-infected patients, due to its minimal drug reactions and greater reduction in lipids and inflammatory markers.
publishDate 2023
dc.date.none.fl_str_mv 2023-12-22
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://afmo.emnuvens.com.br/afmo/article/view/279
10.56102/afmo.2023.279
url https://afmo.emnuvens.com.br/afmo/article/view/279
identifier_str_mv 10.56102/afmo.2023.279
dc.language.iso.fl_str_mv por
eng
language por
eng
dc.relation.none.fl_str_mv https://afmo.emnuvens.com.br/afmo/article/view/279/164
https://afmo.emnuvens.com.br/afmo/article/view/279/163
dc.rights.driver.fl_str_mv Copyright (c) 2023 Thiago José Monteiro Borges da Silva Valente
https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2023 Thiago José Monteiro Borges da Silva Valente
https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Faculdade de Medicina de Olinda
publisher.none.fl_str_mv Faculdade de Medicina de Olinda
dc.source.none.fl_str_mv Annals of Olinda Medical School; Vol. 1 No. 10 (2023); 83-95
Anais da Faculdade de Medicina de Olinda; v. 1 n. 10 (2023); 83-95
2674-8487
2595-1734
reponame:Anais da Faculdade de Medicina de Olinda (Online)
instname:Faculdade de Medicina de Olinda (FMO)
instacron:FMO
instname_str Faculdade de Medicina de Olinda (FMO)
instacron_str FMO
institution FMO
reponame_str Anais da Faculdade de Medicina de Olinda (Online)
collection Anais da Faculdade de Medicina de Olinda (Online)
repository.name.fl_str_mv Anais da Faculdade de Medicina de Olinda (Online) - Faculdade de Medicina de Olinda (FMO)
repository.mail.fl_str_mv anaisfmo@fmo.edu.br
_version_ 1796798260517535744

Registros relacionados